Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

NCT ID: NCT06474078

Last Updated: 2025-09-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-01
• Study Completion Date: 2025-06-20

Brief Summary

The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization. The secondary outcomes are to determine mortality, length of hospitalization, adverse events, the time to beginning of epithelization, the time to halting of progression of SJS/TEN, ocular complications, and infections.

Detailed Description

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) belong to life-threatening severe cutaneous adverse drug reactions. SJS/TEN is classified by the extent of the detachment over the total body-surface area: SJS (<10%), SJS-TEN overlap (10%-30%), and TEN (>30%). TEN has the highest mortality (30-35%); SJS and transitional forms correspond to the same syndrome, but with less extensive skin detachment and a lower mortality (5-15%). Currently, there is still no conclusive effective immunomodulator treatment for SJS/TEN. And, there is still a clinical unmet need for the treatment of SJS/TEN.

According to our past research reports, interleukin-15 (IL-15) plays an important role in SJS/TEN, which is related to disease severity and mortality. Janus kinase (JAK) inhibitors can inhibit the downstream JAK to inhibit the production and transmission of inflammatory cytokines, as a treatment for severe skin drug hypersensitivity reactions. Tofacitinib, a JAK1/3 inhibitor, is an intervention known to effectively treat several inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, a recent study identified a potential therapeutic target with JAK-STAT pathway in a patient with recalcitrant and refractory drug rash with eosinophilia and systemic symptoms (DRESS). Based the current evidence, a targeting therapy to IL-15 by tofacitinib treatment are suggesting likely to be effective in treating SJS/TEN.

This is an "open label" study, all patients enrolled in the study will receive the active medication; meaning that there will not be a placebo or control group. The aims of this project are (1) to investigate the effect of tofacitinib treatment for SJS/TEN patients, including healing time, mortality rate, adverse events, beginning of re-epithelialization time, internal organ recovery time, and ocular complications, and (2) to investigate the molecular mechanism of SJS/TEN after tofacitinib treatment through collection of timed samples to include DNA, RNA, PBMCs, blister cells and supernatant and skin tissue.

The primary outcome of the study is the time to complete re-epithelialization as defined by complete absence of erosion on the skin. The secondary outcomes are to determine the time to beginning of epithelization (defined as the time to start re-epithelialization of the erosions on the skin and mucosa), the time to halting of progression of SJS/TEN (considered significant progression if there are any new blistering lesions or any new detached or detachable skin), mortality, length of hospitalization, ocular complications, infections, and adverse events. The investigators also determine the molecular and cellular mechanisms of SJS/TEN through collection of timed samples to include DNA, RNA, PBMCs, blister cells and supernatant and skin tissue.

Conditions

Stevens-Johnson Syndrome; Toxic Epidermal Necrolysis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tofacitinib treatment

1. Meet the conditions of inclusion and exclusion, seek the consent of the patient

2. Fill out the case report form

3. Blood test and physiological assessment, and do serum granulysin concentration and peripheral blood mononuclear spherical granulysin expression analysis

4. Tofacitinib administration: The experimental group received tofacitinib 5mg-10mg, twice daily, for the first week; and maintained tofacitinib 5mg-10mg, daily, for the second week.

Group Type: EXPERIMENTAL

Tofacitinib

Intervention Type: DRUG

Dosage/Frequency: 5mg - 10mg, oral, twice daily

Interventions

Tofacitinib

Dosage/Frequency: 5mg - 10mg, oral, twice daily

Intervention Type: DRUG

Other Intervention Names

XELJANZ

Eligibility Criteria

Inclusion Criteria

1. Willing to sign inform consent form

2. Subject has been diagnosed with Stevens-Johnson syndrome or toxic epidermal necrolysis by at least two dermatologists.

3. Male or female aged over 20 years old and under 90 years old.

Exclusion Criteria

1. Subject or legally authorized representative is not willing to provide informed consent.

2. Women who are pregnant or breastfeeding

3. Subject has an active, untreated, or serious infectious disease that is ineffective in treatment, such as sepsis.

4. Subject suffers from severe life-threatening cardiac arrhythmia, such as ventricular tachycardia, have had myocardial infarction (myocardial infarction), severe hypertension that has not responded to treatment within the past week, or other cardiologist diagnosed severe cardiovascular disease

5. Subject has active viral hepatitis

6. Subject has active tuberculosis

7. Subject received live vaccination during the illness

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chang Gung Memorial Hospital

OTHER

Sponsor Role: lead

Responsible Party

Chun Bing Chen

Principal Investigator, Clinical Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Chun Bing Chen

Role: PRINCIPAL_INVESTIGATOR

Chang Gung Memorial Hospital

Locations

Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Countries

Taiwan

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

202102411A3

Identifier Type: -

Identifier Source: org_study_id